{"paper_id":"e22a6243-654d-4ec4-bf49-394073c9998c","body_text":"References\nAsch RH, Weckstein LN, Ralmaceda JP, Rojas F, Spitz JM, et al. Non-surgical expulsion of non-viable early pregnancy: a new application of RU 486. Human Reproduction 5: 481–483, 1990\nAubeny E, Baulieu EE. Contragestive activity of RU 486 and oral active prostaglandin combination. Comptes Rendus de L’Academie des Science 312: 539–45, 1991\nBirth Control Trust. The Abortion Pill: Widening the choice for women. The Birth Control Trust, London, 1990\nBrogden RN, Goa KL, Faulds D. Mifepristone. A review of its pharmcodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 44, in press, 1992\nCabrol D, Dubois C, Cronje H, Gonnet JM, Guillot M, et al. Induction of labor with mifepristone (RU 486) in intrauterine fetal death. American Journal of Obstetrics and Gynaecology 163: 540–542, 1990\nCastadot RG. Pregnancy termination: techniques, risks, and complications and their management. Fertility and Sterility 45: 5–17, 1986\nCook RJ. Antiprogestin drugs: medical and legal issues. Family Planning Perspectives 21: 267–272, 1989\nCouzinet B, le Strat N, Silvestre L, Schaison G. Late luteal administration of the antiprogesterone RU 486 in normal women: effects on the menstrual cycle events and fertility control in a long-term study. Fertility and Sterility 54: 1039–1044, 1990\nCrowley WF. Progesterone antagonism. New England Journal of Medicine 315: 1607–1608, 1986\nCsapo AI, Pulkkinen M. Indispensability of the human corpus luteum in the maintenance of early pregnancy luteectomy evidence. Obstetrical and Gynaecological Survey 33: 69–81, 1978\nDubois C, Ulmann A, Baulieu EE. Contragestion with late luteal administration of RU 486 (Mifepristone). Fertility and Sterility 50: 593–596, 1988\nEditorial. Mifepristone: widening the choice for women. Lancet 2: 1112–1113, 1989\nEditorial. A death associated with mifepristone/sulprostone. Lancet 337: 969–970, 1991\nFrank PI, McNamee R, Hannaford PC, Kay CR, Hirsch S. The effect of induced abortion on subsequent pregnancy outcome. British Journal of Obstetrics and Gynaecology 98: 1015–1024, 1991\nFrydman R, Taylor S, Ulmann A. Transplacental passage of mifepristone. Lancet 2: 1252, 1985\nFrydman R, Fernandez H, Pons JC, Ulmann A. Mifepristone (RU486) and therapeutic late pregnancy termination: a double-blind study of two different doses. Human Reproduction 3: 803–806, 1988\nFrydman R, Baton C, Lelaidier C, Vial M, Bourget PH, et al. Mifepristone for induction of labour. Lancet 337: 488–489, 1991\nGlasier A, Thong KJ, Dewar M, Mackie M, Baird DT. Postcoital contraception with mifepristone. Lancet 337: 1414–1415, 1991\nGrunberg SM, Weiss MH, Spitz IM, Ahmadi J, Sadun A, et al. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. Journal of Neurosurgery 74: 861–866, 1991\nGupta JK, Johnson N. Effect of mifepristone on dilation of the pregnant and nonpregnant cervix. Lancet 335: 1238–1240, 1990\nHalbreich U. Treatment of premenstrual syndromes with progesterone antagonists (eg RU 486): political and methodological issues. Psychiatry 53: 407–409, 1990\nHardy RP, New DAT. Effects of the anti-progestin RU 38486 on rat embryos growing in culture. Food and Chemical Toxicology 29: 361–362, 1991\nHeard M, Guillebaud J. Medical abortion. British Medical Journal 304: 195–196, 1992\nHempel S. No easy option. Nursing Times 87: 20–21, 1991\nHenshaw RC, Templeton AA. Pre-operative cervical preparation before first trimester vacuum aspiration: a randomised controlled comparison between gemeprost and mifepristone (RU 436). British Journal of Obstetrics and Gynaecology 98: 1025–1030, 1991\nHenshaw RC, Templeton AA, Naji SA, Russell IT. Medical abortion. Correspondence. British Medical Journal 304: 914, 1992\nHill NCW, Ferguson J, MacKenzie IZ. The efficacy of oral Mifepristone (RU 38,486) with a prostaglandin E1 analog vaginal pessary for the termination of early pregnancy: complications and patient acceptability. American Journal of Obstetrics and Gynecology 162: 414–417, 1990\nHull MGR, Gordon C, Beard RW. The organisation and results of a pregnancy termination service in a national health service hospital. The Journal of Obstetrics and Gynaecology of the British Commonwealth 81: 577–587, 1974\nJoint Study of the Royal College of General Practitioners and the Royal College of Obstetricians and Gynaecologists. Induced abortion operations and their early sequelae. Journal of the Royal College of General Practitioners 35: 175–180, 1985\nKettel LM, Murphy AA, Mortola JF, Liu JH, Ulmann A, et al. Endocrine responses to long-term administration of the antiprogesterone RU 486 in patients with pelvic endometriosis. Fertility and Sterility 56: 402–407, 1991\nKlijn JG, de Jong FH, Bakker GH, Lamberts SW, Rodenburg CJ, et al. Antiprogestins, a new form of endocrine therapy for human breast cancer. Cancer Research 49: 2851–2856, 1989\nKovacs L. Future direction of abortion technology. In Bygdeman M (Ed.) Medical induction of abortion. Bailliere’s Clinical Obstetrics and Gynaecology, Vol. 4, 407–414, Balliere Tindall, London, 1990\nLim BH, Lees, DAR, Bjornsson S, Lunan CB, Cohn MR, et al. Normal development after exposure to mifepristone in early pregnancy. Lancet 336: 257–258, 1990\nLoraine JA. Abortion: world perspectives in the mid-1980s. Family Practice 3: 266–271. 1986\nLuukkainen T, Heinkinheimo O, Haukkamaa M, Lahteenmaki P. Inhibition of folliculogenesis and ovulation by the antiprogsterone RU 486. Fertility and Sterility 49: 961–963, 1988\nMahler H. The safe motherhood initiative: a call to action. Lancet: 668-670, 1987\nMunday D, Francome C, Savage W. Twenty one years of legal abortion. British Medical Journal 298: 1231–1234, 1989\nNieman LK, Chrousos GP, Kellner C, Spitz IM, Nisula BC, et al. Successful treatment of Cushing’s Syndrome with the glucorticoid antagonist RU 486. Journal of Clinical Endocrinology and Metabolism 61: 536–540, 1985\nObel EB. Fertility following legally induced abortion. Acta Obstetrica Gynecologia Scandanavia 58: 539–542, 1979\nPons JC, Imbert MC, Elefant E, Roux C, Herschkorn P, et al. Development after exposure to mifepristone in early pregnancy. Lancet 338: 763, 1991\nReport on Confidential Enquiries into Maternal Deaths in the UK 1985–1987. HMSO, London 1991\nRodger MW, Baird DT. Pretreatment with mifepristone (RU 486) reduces interval between prostaglandin administration and expulsion in second trimester abortion. British Journal of Obstetrics and Gynaecology 97: 41–45, 1990\nSchulz KF, Grimes DA, Cates W. Measures to prevent cervical injury during suction curettage abortion. Lancet 1: 1182–1185, 1983\nSilvestre L, Dubois C, Renault M, Rezvani Y, Baulieu EE, et al. Voluntary interruption of pregnancy with mifepristone (RU 486) and a prostaglandin analogue. New England Journal of Medicine 322: 645–648, 1990\nStuenkel CA, Garzo VG, Morris S, Liu JH, Yen SS. Effects of the antiprogesterone RU 486 in the early follicular phase of the menstrual cycle. Fertility and Sterility 53: 642–646, 1990\nSwahn ML, Bygdeman M. The effect of the antiprogestin RU 486 on uterine contractility and sensitivity to prostaglandin and oxytocin. British Journal of Obstetrics and Gynaecology 95: 126–134, 1988\nUK Multicentre Trial. The efficacy and tolerence of mifepristone and prostaglandin in first trimester termination of pregnancy. British Journal of Obstetrics and Gynaecology 97: 480–486, 1990\nUrquhart DR, Templeton AA. Psychiatric morbidity and acceptability following medical and surgical methods of induced abortion. British Journal of Obstetrics and Gynaecology 98: 396–399, 1991\nUrquhart DR, Templeton AA. The use of mifepristone prior to prostaglandin-induced mid-trimester abortion. Human Reproduction 5: 883–886, 1990\nWolf JP, Chillik CF, Dubois C, Ulmann A, Raulieu EE, et al. Tolerence of perinidatory primate embryos to RU 486 exposure in vitro and in vivo. Contraception 41: 85–92, 1990\nWorld Health Organization. Induced abortion. Technical report series, No. 623, World Health Organization, Geneva, 1978\nYlikorkala O, Alfthan H, Kaariainen M, Rapeli T, Lahteenmaki P. Outpatient therapeutic abortion with mifepristone. Obstetrics and Gynecology 74: 653–657, 1989\nAuthor information\nAuthors and Affiliations\nRights and permissions\nAbout this article\nCite this article\nHenshaw, R.C., Templeton, A.A. Mifepristone. Drugs 44, 531–536 (1992). https://doi.org/10.2165/00003495-199244040-00001\nPublished:\nIssue date:\nDOI: https://doi.org/10.2165/00003495-199244040-00001","source_license":"CC0","license_restricted":false}